- Target Species
- Product Form
- Purified protein - liquid
- Purified protein prepared from human myeloma serum by ion exchange chromatography, gel filtration and protein A chromatography.
- Buffer Solution
- TRIS buffered saline
- Preservative Stabilisers
- 0.1% Sodium Azide (NaN3)
- Approx. Protein Concentrations
- 1.0 mg/ml
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the protein. Should this product contain a precipitate we recommend microcentrifugation before use.
- Guaranteed until date of expiry. Please see product label.
- Entrez Gene
- GO Terms
complement activation, classical pathway
innate immune response
- For research purposes only
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
|Functional Assays 1
- 1This product contains sodium azide, removal by dialysis is recommended prior to use in functional assays. Dialysis cassette (EQU003) is suitable for this purpose.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Application Based External Images
Product Specific References
References for IgG1
Campbell, S. et al. (2006) Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells.
J Immunol. 176:1889-98.
Hershkovitz, O. et al. (2009) NKp44 receptor mediates interaction of the envelope glycoproteins from the West Nile and dengue viruses with NK cells.
J Immunol. 183: 2610-21.
Rosano, J.M. et al. (2009) A physiologically realistic in vitro model of microvascular networks.
Biomed Microdevices. 11 (5): 1051-7.
Arnon, T.I. et al. (2008) Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy.
PLoS One. 3(5): e2150.
Ostrowitzki, S. et al. (2012) Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.
Arch Neurol. 69 (2): 198-207.
Rosental, B. et al. (2011) Proliferating Cell Nuclear Antigen Is a Novel Inhibitory Ligand for the Natural Cytotoxicity Receptor NKp44.
J Immunol. 187: 5693-702.
Bloem, K. et al. (2013) DCIR interacts with ligands from both endogenous and pathogenic origin.
Immunol Lett. pii: S0165-2478(13)00174-0.